Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-162 gene therapy in SOD1-ALS
NCT06100276Phase 2Active, not recruiting
- Sponsor
- uniQure
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Bispecific Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ABP 102 in amyotrophic lateral sclerosis (ALS), sponsored by uniQure. Started Aug 2024; status: active, not recruiting.
02
Drugs
ABP 102
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06100276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100276.